Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis.
about
Prescription channeling of COX-2 inhibitors and traditional nonselective nonsteroidal anti-inflammatory drugs: a population-based case-control studyChemoprevention of colorectal cancerSafety profile of rofecoxib as used in general practice in England: results of a prescription-event monitoring studyPrevention of anti-inflammatory drug-induced gastrointestinal damage: benefits and risks of therapeutic strategiesMeta-analysis: upper gastrointestinal tolerability of valdecoxib, a cyclooxygenase-2-specific inhibitor, compared with nonspecific nonsteroidal anti-inflammatory drugs among patients with osteoarthritis and rheumatoid arthritisDimension reduction and shrinkage methods for high dimensional disease risk scores in historical data.New agents for the medical treatment of interstitial cystitis.High-dimensional propensity score adjustment in studies of treatment effects using health care claims dataEfficacy of methylsulfonylmethane supplementation on osteoarthritis of the knee: a randomized controlled study.Developments in post-marketing comparative effectiveness researchGastroduodenal tolerability of lumiracoxib vs placebo and naproxen: a pilot endoscopic study in healthy male subjects.Rofecoxib: an update on physicochemical, pharmaceutical, pharmacodynamic and pharmacokinetic aspects.Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs.Age and rising rates of cyclooxygenase-2 inhibitor use. Results from a national surveyMeasuring quality in arthritis care: the Arthritis Foundation's quality indicator set for analgesics.Cost-effectiveness analysis for joint pain treatment in patients with osteoarthritis treated at the Instituto Mexicano del Seguro Social (IMSS): Comparison of nonsteroidal anti-inflammatory drugs (NSAIDs) vs. cyclooxygenase-2 selective inhibitors.Effects of stabilization exercise using a ball on mutifidus cross-sectional area in patients with chronic low back painMyths and facts in the use of anti-inflammatory drugs.Managing the adverse effects of nonsteroidal anti-inflammatory drugs.Recent Advances in NSAIDs-Induced Enteropathy Therapeutics: New Options, New Challenges.Synthesis, In Vivo Anti-Inflammatory Activity, and Molecular Docking Studies of New Isatin Derivatives.Rofecoxib in the acute treatment of migraine: a randomized controlled clinical trial.In -silico molecular docking analysis of prodigiosin and cycloprodigiosin as COX-2 inhibitors.Advent of novel phosphatidylcholine-associated nonsteroidal anti-inflammatory drugs with improved gastrointestinal safety.Tolerability profiles of rofecoxib (Vioxx) and Arthrotec. A comparison of six weeks treatment in patients with osteoarthritis.An open-label trial of the selective cyclo-oxygenase-2 inhibitor, rofecoxib, in inflammatory bowel disease-associated peripheral arthritis and arthralgia.Incidence of outpatient physician claims for upper gastrointestinal symptoms among new users of celecoxib, ibuprofen, and naproxen in an insured population in the United States.Experimental study of COX-2 selective and traditional non-steroidal anti-inflammatory drugs in total hip replacement.Modeling risk of gastrointestinal events among Medicaid NSAID users using propensity scores.
P2860
Q24803974-CED8CC09-FFDC-4B3D-BA66-D06E8D5BEFFDQ28192222-203738E9-ECA9-48C6-AF87-59E9439AB53DQ28194919-3A145908-A04F-498F-9B07-C2D431037699Q28200569-A4E0D957-D759-46B1-872C-B4765843FA44Q28218359-4CFED66C-7904-4B86-BC58-1931FDCE3D33Q31070556-B5621663-C839-468F-962B-076F69B0DD00Q32066343-9FD35365-E06F-4C2C-BEE5-C444F750AE1CQ33457966-2D1B49D9-9D2B-4DAC-9C24-EC2A31F6FC97Q33943890-E4DFB7A4-98A9-4D9B-970C-E3E172C6F498Q34001867-56CB1A21-6855-41DD-8EC9-40D68D3B4642Q34536718-6ECEE96A-F94D-458F-BBA6-0A775E07BB49Q35195182-0087A7F4-770C-4FA4-9BBA-A7EBDC0FB241Q35595971-6E5FCD03-812C-4205-BCC2-03E39A1F0CA7Q35688266-B693C798-7798-4015-95FC-8AEACCBBD548Q35799572-4E9F4CB9-D2A0-4F07-BA79-27A5109CD473Q37061561-28052C06-DB69-44A0-81E1-6E9C3AD66747Q37169447-1C6DF812-7BA1-4B2D-AC97-39A211AC8920Q37476911-2C033BA9-6097-487D-B56C-14DCF6BA69B1Q37960540-C4202814-798E-4B34-8D7F-568182DB40CDQ38155495-CB63AF08-B0EC-4857-9FE1-012B36C0A9A9Q38662051-539E6633-CCEA-4A72-B766-2DDA38ADDEDBQ39354736-D290A369-029D-45BF-80F8-A8AAE503CF98Q41191422-4FB59B9A-78F2-4C58-8037-C9DE7385A3B8Q43247710-29A08B5C-4B0B-4213-9674-C60154ADBEF0Q43544496-664494C8-CA5A-43BF-82C6-D215AD0E587DQ44465348-237757E8-0740-48A2-9C61-6336F5839DB3Q44700975-CC102DBF-554F-474A-BF0C-47A61806AF9FQ46042261-2AC8CCC4-1ECA-41B6-B720-1B47CC870D1DQ53060894-F73CDAF4-ADF4-444E-A986-386F622E6AB1
P2860
Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh
2000年學術文章
@zh-hant
name
Gastrointestinal tolerability ...... inhibitors in osteoarthritis.
@en
Gastrointestinal tolerability of the selective cyclooxygenase-2
@nl
type
label
Gastrointestinal tolerability ...... inhibitors in osteoarthritis.
@en
Gastrointestinal tolerability of the selective cyclooxygenase-2
@nl
prefLabel
Gastrointestinal tolerability ...... inhibitors in osteoarthritis.
@en
Gastrointestinal tolerability of the selective cyclooxygenase-2
@nl
P2093
P1476
Gastrointestinal tolerability ...... inhibitors in osteoarthritis.
@en
P2093
P304
P356
10.1001/ARCHINTE.160.19.2998
P407
P577
2000-10-01T00:00:00Z